About RenovoRx, Inc.
https://renovorx.comRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
CEO
Shaun R. Bagai
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
AIGH CAPITAL MANAGEMENT LLC
Shares:2.62M
Value:$2.77M
VANGUARD GROUP INC
Shares:1.61M
Value:$1.7M
BANK OF THE WEST
Shares:975K
Value:$1.03M
Summary
Showing Top 3 of 35
About RenovoRx, Inc.
https://renovorx.comRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $266K ▼ | $3.41M ▲ | $-2.91M ▼ | -1.09K% ▼ | $-0.08 ▼ | $-2.91M ▼ |
| Q2-2025 | $422K ▲ | $2.95M ▼ | $-2.9M ▼ | -686.02% ▲ | $-0.08 ▼ | $-2.68M ▼ |
| Q1-2025 | $197K ▲ | $3.21M ▲ | $-2.42M ▲ | -1.23K% ▲ | $-0.08 ▲ | $-2.42M ▼ |
| Q4-2024 | $43K ▲ | $2.67M ▼ | $-2.88M ▼ | -6.69K% ▼ | $-0.13 ▼ | $0 ▲ |
| Q3-2024 | $0 | $2.83M | $-2.47M | 0% | $-0.1 | $-2.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $10.04M ▼ | $11.21M ▼ | $3.13M ▲ | $8.08M ▼ |
| Q2-2025 | $12.31M ▼ | $13.64M ▼ | $3M ▲ | $10.64M ▼ |
| Q1-2025 | $14.58M ▲ | $16.01M ▲ | $2.86M ▼ | $13.16M ▲ |
| Q4-2024 | $7.15M ▼ | $8.12M ▼ | $3.64M ▲ | $4.48M ▼ |
| Q3-2024 | $9.56M | $10.03M | $2.96M | $7.07M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-2.91M ▼ | $-2.27M ▲ | $0 | $0 ▼ | $-2.27M ▼ | $-2.27M ▲ |
| Q2-2025 | $-2.9M ▼ | $-2.3M ▲ | $0 ▲ | $34K ▼ | $-2.27M ▼ | $-2.3M ▲ |
| Q1-2025 | $-2.42M ▲ | $-3.38M ▼ | $-2K ▲ | $10.81M ▲ | $7.43M ▲ | $-3.38M ▼ |
| Q4-2024 | $-2.88M ▼ | $-2.43M ▼ | $-12K ▼ | $33K ▲ | $-2.41M ▼ | $-2.44M ▼ |
| Q3-2024 | $-2.47M | $-2.19M | $0 | $15K | $-2.18M | $-2.19M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Other Operating Segment | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Shaun R. Bagai
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
AIGH CAPITAL MANAGEMENT LLC
Shares:2.62M
Value:$2.77M
VANGUARD GROUP INC
Shares:1.61M
Value:$1.7M
BANK OF THE WEST
Shares:975K
Value:$1.03M
Summary
Showing Top 3 of 35